journal article·2019-07

Injectable biomaterials for delivery of interleukin-1 receptor antagonist: Toward improving its therapeutic effect

Anna E.B. Clements, William L. Murphy

Acta Biomaterialia· Volume 93
Publisher page

Abstract

Interleukin-1 receptor antagonist (IL-1Ra) is a naturally occurring anti-inflammatory cytokine that inhibits IL-1 activity and has been proposed to treat a wide variety of systemic and local inflammatory pathologies for multiple decades. However, the short half-life and high concentration required to inhibit IL-1 activity has limited its use in clinical applications. Many strategies have been developed with the goal of improving the therapeutic efficacy of IL-1Ra for a variety of pathologies, including fusing IL-1Ra to protein/peptide/polymer partners, releasing IL-1Ra from injectable polymer or mineral particles, and release of IL-1Ra from injectable coacervates and gels. This literature review examines injectable biomaterials engineered to improve IL-1Ra delivery, both locally and systemically, to increase its efficacy and ease of use in clinic. STATEMENT OF SIGNIFICANCE: Interleukin-1 receptor antagonist (IL-1Ra) is a therapeutic protein with the potential to treat numerous inflammatory conditions and diseases. However, its short biological half-life and high therapeutic concentration may limit its utility in all but a few clinical scenarios. In this review, we present the biomaterial based delivery strategies which have been explored to deliver IL-1Ra to improve its efficacy and applicability to treat inflammation.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Advanced Drug Delivery Systems · RNA Interference and Gene Delivery · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-110.1056/NEJM200009073431011 ↗
2. Role of interleukin-1beta during pain and inflammation10.1016/j.brainresrev.2008.12.020 ↗
3. The IL-1 family: regulators of immunity10.1038/nri2691 ↗
4. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases10.1182/blood-2010-07-273417 ↗
5. Interleukin-1 (IL-1) Pathway
6. Immunological and inflammatory functions of the interleukin-1 family10.1146/annurev.immunol.021908.132612 ↗
7. Interleukin-1 receptor antagonist as therapy for inflammatory disorders10.1517/14712598.1.2.301 ↗
8. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders10.1111/j.1365-2249.2007.03441.x ↗
9. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis10.1007/BF02850127 ↗
10. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus10.1002/jps.23057 ↗
11. Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus10.1002/jcb.24402 ↗
12. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer’s disease10.1136/jnnp.74.6.788 ↗
13. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology10.1172/JCI31450 ↗
14. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra10.1016/j.nbd.2006.06.013 ↗
15. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease10.1093/brain/awn101 ↗
16. Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma10.1196/annals.1391.022 ↗
17. Interleukin-1 and inflammatory neurodegeneration10.1042/BST0351122 ↗
18. The role of IL-1 in the pathogenesis of heart disease10.1007/s00005-009-0024-y ↗
19. Interleukin-1 receptor antagonist modulates inflammation and scarring after ligament injury10.3109/03008207.2014.906408 ↗
20. Interleukin-1 and acute brain injury10.3389/fncel.2015.00018 ↗
21. IL-1Ra and its delivery strategies: inserting the association in perspective10.1007/s11095-013-1118-0 ↗
22. Biologic basis for interleukin-1 in disease10.1182/blood.V87.6.2095.bloodjournal8762095 ↗
23. Biodistribution, pharmacokinetics and metabolism of interleukin-1 receptor antagonist (IL-1RA) using [18F]-IL1RA and PET imaging in rats10.1111/j.1476-5381.2010.01068.x ↗
24. A brief history of IL-1 and IL-1Ra in rheumatology
25. Targeting interleukin-1 in the treatment of rheumatoid arthritis10.1002/art.10168 ↗
26. The role of interleukin-1 in pathogenesis of rheumatoid arthritis10.1093/rheumatology/keh201 ↗
27. The role of Interleukin-1 inhibitors in osteoarthritis10.2165/11599350-000000000-00000 ↗
28. Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy10.1186/ar3436 ↗
29. Osteoarthritis: can anti-cytokine therapy play a role in treatment10.1007/s10067-009-1352-3 ↗
30. Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1a and -1b, and NLRP3 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis
31. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression10.1016/S0002-9440(10)65368-0 ↗
32. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene10.1038/sj.gt.3301608 ↗
33. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis, Suppression of collagenase-1 expression10.1002/art.1780390914 ↗
34. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study
35. Intraarticular injection of Anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study10.1002/art.24096 ↗
36. Post-traumatic arthritis: overview on pathogenic mechanisms and role of inflammation10.1136/rmdopen-2016-000279 ↗
37. Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis10.1186/ar4591 ↗
38. Interleukin expression after injury and the effects of interleukin-1 receptor antagonist10.1371/journal.pone.0071631 ↗
39. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament injury: a randomized controlled pilot trial (NCT00332254)10.1016/j.joca.2011.12.009 ↗
40. Progress in intra-articular therapy10.1038/nrrheum.2013.159 ↗
41. Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders10.1002/jps.21346 ↗
42. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs10.1016/j.xphs.2015.11.015 ↗
43. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist10.1016/j.bmc.2007.05.061 ↗
44. Albumin as a versatile platform for drug half-life extension
45. Purification of fusion protein HSA/IL1ra and its bioactivity
46. The effect of gene copy number and co-expression of chaperone on production of albumin fusion proteins in Pichia pastoris10.1007/s00253-012-4337-0 ↗
47. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion10.1186/1472-6750-12-68 ↗
48. Aggregation-resistant domain antibodies selected on phage by heat denaturation10.1038/nbt1000 ↗
49. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli10.1038/341544a0 ↗
50. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs10.1093/protein/gzm067 ↗
51. Self-assembling nanoparticles for intra-articular delivery of anti-inflammatory proteins10.1016/j.biomaterials.2012.06.101 ↗
52. Synthesis of self-assembled IL-1Ra-presenting nanoparticles for the treatment of osteoarthritis10.1002/jbm.a.35601 ↗
53. Self-assembled raspberry-like core/satellite nanoparticles for anti-inflammatory protein delivery10.1021/acsami.6b16277 ↗
54. Polymer microspheres for controlled drug release10.1016/j.ijpharm.2004.04.013 ↗
55. Functional polymer microspheres10.1016/S0079-6700(00)00024-1 ↗
56. Bioadhesive microspheres as a controlled drug delivery system10.1016/S0378-5173(03)00087-5 ↗
57. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide)10.1038/71916 ↗
58. pH and osmotic pressure inside biodegradable microspheres during erosion10.1023/A:1018822002353 ↗
59. In vitro assessment of the biological activity of basic fibroblast growth factor released from various polymers and biomatrices10.1177/088532829701200103 ↗
60. Biodegradable microspheres for protein delivery10.1016/S0168-3659(03)00194-9 ↗
61. Delivery of therapeutic proteins10.1002/jps.22054 ↗
62. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems10.1615/CritRevTherDrugCarrierSyst.v19.i1.20 ↗
63. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties10.3109/02652049009021842 ↗
64. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier10.3390/polym3031377 ↗
65. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres10.1023/A:1015841715384 ↗
66. Degradation of poly(d,l-lactic acid) microspheres: effect of molecular weight10.1016/0168-3659(94)90263-1 ↗
67. Controlled release from bioerodible polymers: effect of drug type and polymer composition10.1016/j.jconrel.2004.10.019 ↗
68. Effect of acidic pH on PLGA microsphere degradation and release10.1016/j.jconrel.2007.05.034 ↗
69. protein instability in poly(lactic-co-glycolic acid) microparticles10.1023/A:1026498209874 ↗
70. PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches10.3109/10837450.2014.882940 ↗
71. IL-1ra delivered from poly(lactic-co-glycolic acid) microspheres attenuates IL-1β-mediated degradation of nucleus pulposus in vitro10.1186/ar3932 ↗
72. Sustained release of IL-1Ra from biodegradable microspheres prolongs its IL-1-neutralizing effects10.1560/DYBG-TWDV-J8PF-7W9T ↗
73. Sustained release of IL-1Ra from biodegradable microspheres prolongs its IL-1-neutralizing effects10.1560/DYBG-TWDV-J8PF-7W9T ↗
74. Drug delivery from gelatin-based systems10.1517/17425247.2015.1037272 ↗
75. Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-210.1016/j.actbio.2008.04.002 ↗
76. Controlled release of growth factors based on biodegradation of gelatin hydrogel10.1163/156856201744461 ↗
77. Biodegradation of hydrogel carrier incorporating fibroblast growth factor10.1089/ten.1999.5.127 ↗
78. The graft survival protection of subcutaneous allogeneic islets with hydrogel grafting and encapsulated by CTLA4Ig and IL1ra10.1038/pj.2013.71 ↗
79. Controlled release of a model protein from enzymatically degrading dextran microspheres10.1016/S0168-3659(98)00193-X ↗
80. Development of dextran microparticles loaded with IL-1Ra of high-encapsulation efficiency and high-bioactivity by a novel method without exposing IL-1Ra to water–oil interfaces10.1016/j.powtec.2012.10.036 ↗
81. Controlled release of interleukin-1 receptor antagonist from hyaluronic acid-chitosan microspheres attenuates interleukin-1β-induced inflammation and apoptosis in chondrocytes10.1155/2016/6290957 ↗
82. Chitosan—A versatile semi-synthetic polymer in biomedical applications10.1016/j.progpolymsci.2011.02.001 ↗
83. Chitosan, hyaluronan and chondroitin sulfate in tissue engineering for cartilage regeneration: a review10.1016/j.carbpol.2012.04.057 ↗
84. Protein chromatography on hydroxyapatite columns10.1016/S0076-6879(09)63024-X ↗
85. Bioinspired growth of crystalline carbonate apatite on biodegradable polymer substrata10.1021/ja012433n ↗
86. Mineral coatings for temporally controlled delivery of multiple proteins10.1002/adma.201100060 ↗
87. Nanostructured mineral coatings stabilize proteins for therapeutic delivery10.1002/adma.201701255 ↗
88. Multilayered inorganic microparticles for tunable dual growth factor delivery10.1002/adfm.201302859 ↗
89. Mineral coatings modulate β-TCP stability and enable growth factor binding and release10.1016/j.actbio.2011.11.028 ↗
90. Growth of hydroxyapatite coatings on biodegradable polymer microspheres10.1021/am9001716 ↗
91. Microparticles locally deliver active interleukin-1 receptor antagonist in vivo10.1002/adhm.201800263 ↗
92. Addition of mineral-coated microparticles to soluble interleukin-1 receptor antagonist injected subcutaneously improves and extends systemic interleukin-1 inhibition
93. Peptide-based biopolymers in biomedicine and biotechnology10.1016/j.mser.2008.04.004 ↗
94. A thermally responsive biopolymer for intra-articular drug delivery10.1016/j.jconrel.2006.07.022 ↗
95. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic10.1002/art.22952 ↗
96. The effect of covalently immobilized rhIL-1ra-ELP fusion protein on the inflammatory profile of LPS-stimulated human monocytes10.1016/j.biomaterials.2007.04.010 ↗
97. Sustained intra-articular delivery of IL-1Ra from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis10.22203/eCM.v029a10 ↗
98. Sustained delivery of IL-1Ra from PF127-Gel reduces hyperglycemia in diabetic GK-rats10.1371/journal.pone.0055925 ↗
99. Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials10.1007/s11095-012-0843-0 ↗
100. Gene delivery to joints by intra-articular injection10.1089/hum.2017.181 ↗